HIF1A and triple-A syndrome: Previous experiments demonstrate the ability of the HIF1a inhibitor to both suppress experimental AAA initiation and stabilize existing aneurysms, through mechanisms likely related to impair mural macrophage infiltration and angiogenesis20,32.